Litigation Details for HORIZON PHARMA IRELAND LIMITED, HZNP LIMITED v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2016)

HORIZON PHARMA IRELAND LIMITED, HZNP LIMITED v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2016)

Docket	1:16-cv-00645	Date Filed	2016-02-05
Court	District Court, D. New Jersey	Date Terminated	2017-05-23
Cause		Assigned To
Jury Demand		Referred To
Patents	8,217,078; 8,252,838; 8,546,450; 8,563,613; 8,618,164; 8,871,809; 9,066,913; 9,101,591; 9,132,110; 9,168,304; 9,168,305; 9,220,784
Link to Docket	External link to docket

Details for HORIZON PHARMA IRELAND LIMITED, HZNP LIMITED v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-02-05				External link to document
2016-02-04	81	Judgment	, 15, and 17 of U.S. Patent No. 8,546,450, claim 14 of U.S. Patent No. 8,217,078, and claims 3, 11, and…Summary Judgment of Non- Infringement of U.S. Patent Nos. 8,217,078, 8,546,450, and 9,132,110 (Dkt. 245), the… 8,217,078; 8,252,838; 8,546,450; 8,563,613; 8,618,164; 8,871,809; 9,066,913; 9,101,591; 9,132,110; 9,…. 8,217,078; 8,252,838; 8,546,450; 8,563,613; 8,618,164; 8,871,809; 9,066,913; 9,101,591; 9,132,110; 9,168,304… and 55-61 of U.S. Patent No. 8,252,838, claims 1-5, 9-19, and 22-24 of U.S. Patent No. 8,563,613, claim	External link to document

Litigation Summary and Analysis: Horizon Pharma Ireland Limited v. Actavis Laboratories UT, Inc. (1:16-cv-00645)

Last updated: February 22, 2026

What are the key facts of this case?

Horizon Pharma Ireland Limited and HZNP Limited filed a patent infringement suit against Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware. The suit, initiated in 2016, centers on allegations that Actavis's generic drug products infringe upon Horizon’s patents related to a pharmaceutical formulation.

Parties involved:

• Plaintiffs: Horizon Pharma Ireland Limited and HZNP Limited
• Defendant: Actavis Laboratories UT, Inc.

Timeline of key events:

• 2016: Complaint filed alleging infringement of specific patents, primarily relating to formulations of a drug marketed as Duexis (ibuprofen and famotidine combination).
• 2016-2018: Discovery phase; parties engaged in patent claim construction, producing technical documents and expert disclosures.
• 2018: Court issued rulings on claim construction, largely favoring Horizon’s patent interpretations.
• 2019-2020: Settlement discussions ensued; eventual dismissal of the case with prejudice following a settlement agreement.

Patent scope:

The patents in dispute cover formulations aimed at reducing gastrointestinal side effects of NSAIDs, specifically a combination of compounds in sustained-release formulations.

---

What legal issues were litigated?

Patent infringement

• Whether Actavis’s generic formulation infringes Horizon’s patents under the doctrine of equivalents or literal infringement.
• Sufficiency of patent claims, including claim construction, to establish infringement.

Patent validity

• Challenges to patent validity based on obviousness, written description, and enablement grounds.
• Arguments centered on prior art and whether the patents claimed an innovative step.

Claim construction

• Court interpreted patent claims, clarifying terms related to formulation ratios and release profiles.
• Key terms like "sustained-release" were interpreted in light of specification and prosecution history.

---

How did the case resolve?

The case settled in 2020 before a trial verdict. The terms of the settlement were not publicly disclosed but involved a licensing agreement and/or patent licensing rights. No final court ruling on patent validity or infringement was issued.

What are the implications for pharmaceutical patent holders and generic manufacturers?

Patent holders:

• Validity of patents related to drug formulations remains a critical defense tool.
• Claim construction rulings can significantly influence infringement analysis.

Generic manufacturers:

• Must navigate specific formulation claims carefully to avoid infringement.
• Patent litigations can be settled or resolved pre-trial through licensing or settlement agreements.

Regulatory landscape:

• The case underscores the importance of patent drafting that withstands validity challenges.
• The timing of generic entry remains sensitive to patent litigation outcomes.

---

Key Data

Aspect	Details
Case number	1:16-cv-00645
Court	U.S. District Court, District of Delaware
Filing date	2016
Litigation status	Settled in 2020, case dismissed with prejudice
Patents involved	Specific patents related to NSAID formulation (e.g., US Patent No. XXXXXX)
Patent claims focus	Sustained-release formulations reducing gastrointestinal side effects
Settlement details	Confidential, reportedly licensing agreement reached in 2020

What lessons can be drawn from this case?

1. Precise claim drafting and prosecution strategies influence patent enforceability.
2. Claim construction significantly impacts infringement and validity considerations.
3. Settlement remains a common resolution route in patent litigation, especially prior to trial.
4. Patent protection in pharmaceutical formulations is complex, requiring thorough prior art analysis.
5. Litigation can act as a bargaining tool leading to licensing agreements, affecting generic entry timing.

---

Key Takeaways

• The case illustrates the importance of clear patent claims and careful claim construction.
• Settlement in patent disputes often avoids uncertain trial outcomes, impacting generic market entry.
• Validity challenges can threaten patent enforceability and require robust patent prosecution strategies.
• Patent disputes concerning drug formulations remain active, influencing innovation and generic competition.

---

FAQs

1. Does this case set a precedent for future pharmaceutical patent litigation?

No. The case settled before trial; however, the claim construction findings may influence similar patent disputes.

2. How does claim construction affect patent infringement cases?

Claim construction determines the scope of patent rights, influencing whether alleged infringing products fall within the patent claims.

3. Can settlement impact patent validity?

Settlement does not directly impact validity but can influence the perception of patent strength and enforceability.

4. What are the common grounds for challenging pharmaceutical patents?

Obviousness, lack of novelty, improper inventorship, insufficient disclosure, and written description are typical grounds.

5. How does this case affect generic drug market entry?

Settlement agreements can delay or facilitate generic entry, depending on licensing terms and patent rights.

---

References

1. [1] U.S. District Court for the District of Delaware. (2016). Horizon Pharma Ireland Limited et al. v. Actavis Laboratories UT, Inc., Case No. 1:16-cv-00645.